Tags

Type your tag names separated by a space and hit enter

Increased levels of angiopoietin-2 in induced sputum from smoking asthmatic patients.
Clin Exp Allergy. 2009 Sep; 39(9):1330-7.CE

Abstract

BACKGROUND

Active cigarette smoking has detrimental effects on asthma morbidity and severity. Angiopoietin-1 has been shown to protect the microvessels against plasma leakage, whereas angiopoietin-2 enhances vascular permeability and subsequently induces airway mucosal oedema. Therefore, it is recently thought that angiopoietin-2 may contribute to the pathophysiology of asthma.

OBJECTIVE

To determine whether angiopoietin-2 levels in the airways are associated with clinical profiles in smoking asthmatics.

METHODS

We measured angiopoietin-1 and -2 levels in induced sputum in 35 normal controls (18 non-smokers and 17 smokers) and 49 asthmatics (24 non-smokers and 25 smokers) before and after inhaled beclomethasone dipropionate (BDP: 800 microg/day) therapy for 12 weeks.

RESULTS

Angiopoietin-1 and -2 levels in induced sputum were significantly higher in asthmatics than in normal controls. Moreover, angiopoietin-2 levels were significantly higher in smoking asthmatics than in non-smoking asthmatics (P=0.0001). The airway vascular permeability index was also higher in smoking asthmatics than in non-smoking asthmatics. Moreover, the angiopoietin-2 level was positively correlated with the airway vascular permeability index (non-smoking asthmatics: r=0.87, P<0.001, smoking asthmatics: r=0.64, P=0.002). After BDP therapy, angiopoietin-1 levels were significantly decreased in non-smoking asthmatics, smoking-cessation asthmatics, and active-smoking asthmatics. In contrast, angiopoietin-2 levels did not differ from before to after BDP therapy in non-smoking asthmatics and active-smoking asthmatics. However, its levels were significantly decreased from before to after BDP therapy in smoking-cessation asthmatics (P=0.002). Although forced expiratory volume in 1 s (FEV(1))/forced vital capacity (FVC) before BDP therapy was comparable in all subgroups, this parameter after BDP therapy was significantly lower in active-smoking asthmatics than in non-smoking and smoking-cessation asthmatics. Moreover, the reduction in angiopoietin-2 levels after BDP therapy in smoking-cessation asthmatics was significantly correlated with an improvement in FEV(1)/FVC.

CONCLUSION

Angiopoietin-2 levels were elevated in the airways of smoking asthmatics, and its levels were associated with impaired airway responses.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Kanazawa H
Department of Respiratory Medicine, Graduate School of Medicine, Osaka City University, Osaka, Japan. kanazawa-h@med.osaka-cu.ac.jp
Asai K
No affiliation info available
Tochino Y
No affiliation info available
Kyoh S
No affiliation info available
Kodama T
No affiliation info available
Hirata K
No affiliation info available

MeSH

AdultAngiopoietin-1Angiopoietin-2Anti-Asthmatic AgentsAsthmaBeclomethasoneCapillary PermeabilityEdemaFemaleForced Expiratory VolumeHumansMaleRespiratory MucosaSmokingSmoking CessationSputum

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19438587

Citation

Kanazawa, H, et al. "Increased Levels of Angiopoietin-2 in Induced Sputum From Smoking Asthmatic Patients." Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology, vol. 39, no. 9, 2009, pp. 1330-7.
Kanazawa H, Asai K, Tochino Y, et al. Increased levels of angiopoietin-2 in induced sputum from smoking asthmatic patients. Clin Exp Allergy. 2009;39(9):1330-7.
Kanazawa, H., Asai, K., Tochino, Y., Kyoh, S., Kodama, T., & Hirata, K. (2009). Increased levels of angiopoietin-2 in induced sputum from smoking asthmatic patients. Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology, 39(9), 1330-7. https://doi.org/10.1111/j.1365-2222.2009.03262.x
Kanazawa H, et al. Increased Levels of Angiopoietin-2 in Induced Sputum From Smoking Asthmatic Patients. Clin Exp Allergy. 2009;39(9):1330-7. PubMed PMID: 19438587.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Increased levels of angiopoietin-2 in induced sputum from smoking asthmatic patients. AU - Kanazawa,H, AU - Asai,K, AU - Tochino,Y, AU - Kyoh,S, AU - Kodama,T, AU - Hirata,K, Y1 - 2009/04/28/ PY - 2009/5/15/entrez PY - 2009/5/15/pubmed PY - 2009/11/18/medline SP - 1330 EP - 7 JF - Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology JO - Clin Exp Allergy VL - 39 IS - 9 N2 - BACKGROUND: Active cigarette smoking has detrimental effects on asthma morbidity and severity. Angiopoietin-1 has been shown to protect the microvessels against plasma leakage, whereas angiopoietin-2 enhances vascular permeability and subsequently induces airway mucosal oedema. Therefore, it is recently thought that angiopoietin-2 may contribute to the pathophysiology of asthma. OBJECTIVE: To determine whether angiopoietin-2 levels in the airways are associated with clinical profiles in smoking asthmatics. METHODS: We measured angiopoietin-1 and -2 levels in induced sputum in 35 normal controls (18 non-smokers and 17 smokers) and 49 asthmatics (24 non-smokers and 25 smokers) before and after inhaled beclomethasone dipropionate (BDP: 800 microg/day) therapy for 12 weeks. RESULTS: Angiopoietin-1 and -2 levels in induced sputum were significantly higher in asthmatics than in normal controls. Moreover, angiopoietin-2 levels were significantly higher in smoking asthmatics than in non-smoking asthmatics (P=0.0001). The airway vascular permeability index was also higher in smoking asthmatics than in non-smoking asthmatics. Moreover, the angiopoietin-2 level was positively correlated with the airway vascular permeability index (non-smoking asthmatics: r=0.87, P<0.001, smoking asthmatics: r=0.64, P=0.002). After BDP therapy, angiopoietin-1 levels were significantly decreased in non-smoking asthmatics, smoking-cessation asthmatics, and active-smoking asthmatics. In contrast, angiopoietin-2 levels did not differ from before to after BDP therapy in non-smoking asthmatics and active-smoking asthmatics. However, its levels were significantly decreased from before to after BDP therapy in smoking-cessation asthmatics (P=0.002). Although forced expiratory volume in 1 s (FEV(1))/forced vital capacity (FVC) before BDP therapy was comparable in all subgroups, this parameter after BDP therapy was significantly lower in active-smoking asthmatics than in non-smoking and smoking-cessation asthmatics. Moreover, the reduction in angiopoietin-2 levels after BDP therapy in smoking-cessation asthmatics was significantly correlated with an improvement in FEV(1)/FVC. CONCLUSION: Angiopoietin-2 levels were elevated in the airways of smoking asthmatics, and its levels were associated with impaired airway responses. SN - 1365-2222 UR - https://www.unboundmedicine.com/medline/citation/19438587/Increased_levels_of_angiopoietin_2_in_induced_sputum_from_smoking_asthmatic_patients_ L2 - https://doi.org/10.1111/j.1365-2222.2009.03262.x DB - PRIME DP - Unbound Medicine ER -